scholarly journals The Hypocholesterolemic Effects of Eryngium carlinae F. Delaroche Are Mediated by the Involvement of the Intestinal Transporters ABCG5 and ABCG8

2017 ◽  
Vol 2017 ◽  
pp. 1-7 ◽  
Author(s):  
Ibrahim Guillermo Castro-Torres ◽  
Minarda De la O-Arciniega ◽  
Elia Brosla Naranjo-Rodríguez ◽  
Víctor Alberto Castro-Torres ◽  
Miguel Ángel Domínguez-Ortíz ◽  
...  
Keyword(s):  
Hdl Cholesterol ◽  
Lipid Lowering ◽  
Hypocholesterolemic Effect ◽  
High Concentration ◽  
Hydroalcoholic Extract ◽  
Western Blot Method ◽  
Intestinal Transporters ◽  
Biochemical Analyses ◽  
Histopathological Studies ◽  
Lipid Lowering Effect

Hypercholesterolemia is a metabolic disorder characterized by a high concentration of cholesterol in the blood. Eryngium carlinae is a medicinal plant used to treat lipid diseases. The goal of this work was to evaluate, in a model of hypercholesterolemia in mice, the hypocholesterolemic effect of a hydroalcoholic extract of E. carlinae and its main metabolite, D-mannitol. Biochemical analyses of serum lipids and hepatic enzymes were performed by photocolorimetry. We performed histopathological studies of the liver and the expression of the intestinal cholesterol transporters Abcg5 and Abcg8 was determined by standard western blot method. Our results showed that hydroalcoholic extract at doses of 100 mg/kg and D-mannitol at doses of 10 mg/kg reduced the concentration of both total cholesterol and non-HDL cholesterol, without altering the concentration of HDL cholesterol and without damage to hepatocytes. Treatment with the extract increased Abcg8 intestinal transporter expression, while D-mannitol decreased the expression of the two Abcg5/Abcg8 transporters, compared with the hypercholesterolemic group. Considering that Abcg5/Abcg8 transporters perform cholesterol efflux, our results demonstrate that the lipid-lowering effect of the hydroalcoholic extract may be associated with the increase of Abcg8 expression, but the hypocholesterolemic effect of D-mannitol is independent of overexpression of these intestinal transporters and probably they have another mechanism of action.

scholarly journals Isolated soya protein with standardised levels of isoflavones, cotyledon soya fibres and soya phospholipids improves plasma lipids in hypercholesterolaemia: a double-blind, placebo-controlled trial of a yoghurt formulation

2004 ◽  
Vol 91 (3) ◽  
pp. 393-401 ◽  
Author(s):  
Pekka Puska ◽  
Vesa Korpelainen ◽  
Lars H. Høie ◽  
Eva Skovlund ◽  
Knut T. Smerud
Keyword(s):  
Ldl Cholesterol ◽  
Intervention Group ◽  
Gastrointestinal Symptoms ◽  
Hdl Cholesterol ◽  
Dropout Rate ◽  
Soya Protein ◽  
Lipid Lowering ◽  
Control Group ◽  
Lowering Effect ◽  
Lipid Lowering Effect

The objective was to study whether a yoghurt containing isolated soya protein with standardised levels of isoflavones, cotyledon soya fibres and soya phospholipids is more effective in lowering total and LDL-cholesterol than a placebo. One hundred and forty-three subjects were randomised to the soya group (n69) or to the placebo (n74). The mean baseline levels were 7·6 and 5·1mmol/l for total and LDL-cholesterol, respectively. Fasting serum lipoproteins were assessed five times during the 8-week intervention period, and 4 weeks thereafter. The results were analysed by a mixed model for unbalanced repeated measurements. During the intervention, there were highly significant differences in lipid-lowering effect in favour of the active soya intervention group compared with the control group. The significant differences were for total cholesterol (estimated mean difference 0·40mmol/l;P<0·001), LDL-cholesterol (0·39mmol/l;P<0·001), non-HDL-cholesterol (0·40mmol/l;P<0·001) and for the total:HDL-cholesterol ratio (0·23;P=0·005). There was no difference in the effects on HDL-cholesterol, triacylglycerols or homocysteine. The lipid-lowering effect occurred within 1–2 weeks of intervention, and was not due to weight loss. The safety profile for active soya was similar to the placebo group, except for gastrointestinal symptoms, which caused a significantly higher dropout rate (fourteenv. three subjects) among the subjects taking active soya.

Study of Antihyperglycemic, Antihyperlipidemic and Antioxidant Activities of Tannins Extracted from Warionia saharae Benth. & Coss

2019 ◽  
Vol 19 (2) ◽  
pp. 189-198 ◽  
Author(s):  
Mohammed Ajebli ◽  
Fadwa El Ouady ◽  
Mohamed Eddouks
Keyword(s):  
Antioxidant Activity ◽  
Antioxidant Activities ◽  
Histopathological Examination ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Diabetic Rats ◽  
Lipid Lowering ◽  
Glucose Levels ◽  
Soxhlet Apparatus

Background and Objective: Warionia saharae Benth & Coss, a plant belonging to Asteraceae family, is used for its anti-diabetic properties in Morocco. The objective of this study was to evaluate the effect of tannins extracted from Warionia saharae (W. saharae) on blood glucose levels and lipid profile in normal and streptozotocin(STZ)-induced diabetic rats. Methods: Tannins (TE) were extracted from W. saharae using Soxhlet apparatus and different organic solvents. Single and once daily repeated oral administration of TE (10 mg/kg) for 15 days were used to evaluate the glucose and lipid-lowering activity in normal and diabetic rats. Furthermore, glucose test tolerance, liver histopathological examination and in vitro antioxidant activity of TE were carried out in this study. Results: The results showed that TE was able to exert antihyperglycemic and lowering total cholesterol effects as well as improvement of the high-density lipoprotein (HDL)-cholesterol serum level after 15 days of treatment. Furthermore, TE improved glucose tolerance, histopathological status of liver in diabetic rats and demonstrated interesting antioxidant activity. Conclusion: In conclusion, the present investigation revealed that TE possesses potent antidiabetic and antihyperlipidemic activities as claimed in different ethnopharmacological practices.

Does chenodesoxycholic acid have a lipid lowering effect in primary hyperlipoproteinemia?

1976 ◽  
Vol 10 (2) ◽  
pp. 147-149 ◽  
Author(s):  
G. Schlierf ◽  
A. Stiehl ◽  
C. C. Heuck ◽  
P. D. Lang ◽  
P. Oster ◽  
...  
Keyword(s):  
Lipid Lowering ◽  
Lowering Effect ◽  
Lipid Lowering Effect

scholarly journals Lipid-lowering effect of tenofovir in HIV-infected patients

2010 ◽  
Vol 66 (3) ◽  
pp. 682-683 ◽  
Author(s):  
M. Fabbiani ◽  
L. Bracciale ◽  
M. Doino ◽  
L. Sidella ◽  
S. Farina ◽  
...  
Keyword(s):  
Lipid Lowering ◽  
Lowering Effect ◽  
Lipid Lowering Effect

scholarly journals Antiobesity Activity of Elateriospermum tapos Shell Extract in Obesity-Induced Sprague Dawley Rats

Molecules ◽  
2021 ◽  
Vol 26 (2) ◽  
pp. 321
Author(s):  
Kokila Vani Perumal ◽  
Nor Liyana Ja’afar ◽  
Che Norma Mat Taib ◽  
Nurul Husna Shafie ◽  
Hasnah Bahari
Keyword(s):  
Body Weight ◽  
Corn Starch ◽  
Milk Powder ◽  
Caloric Intake ◽  
Lipid Lowering ◽  
Sprague Dawley ◽  
Triglyceride Accumulation ◽  
Sprague Dawley Rats ◽  
Effective Result ◽  
Lipid Lowering Effect

Obesity is one of the risk factors associated with cardiovascular diseases, hypertension, abnormal liver function, diabetes, and cancers. Orlistat is currently available to treat obesity, but it is associated with adverse side effects. Natural resources are widely used for obesity treatment. Hence, this study aimed to investigate the anti-obesity activity of Elateriospermum tapos (E. tapos) shell extract in obesity induced Sprague Dawley rats. The rats’ obesity was induced by a high-fat (HF) diet made up of 50% standard rat pellet, 20% milk powder, 6% corn starch, and 24% ghee and a cafeteria (CAF) diet such as chicken rolls, salty biscuits, cakes, and cheese snacks. A hot aqueous method for the extraction of E. tapos shells was applied by using 500 mL of distilled water for about 24 h. Various dosages of E. tapos shell extract (10 mg/kg, 100 mg/kg, and 200 mg/kg) were used. At the end of the study, body weight, caloric intake, organ weight, lipid profile, lipoprotein lipase (LPL) activity, and histopathology analysis were carried out. E. tapos shell extract treated groups showed a reduction in body weight, positive lipid-lowering effect, decrements in triglyceride accumulation and LPL activity, and positive improvement in histopathology analysis. A dose of 200 mg/kg showed the most effective result compared to 10 mg/kg and 100 mg/kg doses.

scholarly journals KIF6 gene as a pharmacogenetic marker for lipid-lowering effect in statin treatment

PLoS ONE ◽  
2018 ◽  
Vol 13 (10) ◽  
pp. e0205430 ◽  
Author(s):  
Cristina Ruiz-Iruela ◽  
Ariadna Padró-Miquel ◽  
Xavier Pintó-Sala ◽  
Neus Baena-Díez ◽  
Assumpta Caixàs-Pedragós ◽  
...  
Keyword(s):  
Statin Treatment ◽  
Lipid Lowering ◽  
Lowering Effect ◽  
Lipid Lowering Effect
Sign in / Sign up

Export Citation Format

Share Document